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6–42 g/ml (days 4–6), in synchrony with the T-cell nadirs, and
became undetectable by day 13. Antibodies to rabbit ATG ap-
peared after 6–7 days, and their titers increased as ATG was
cleared from the circulation. We then evaluated the immunosup-
pressive effects of ATG using allogeneic skin grafts. Median skin
graft survival in 5 dogs given ATG was 14 days, compared to 8 days
among 28 controls (p  0.0003). Based on these observations, an
HCT protocol was designed; 5 dogs were given ATG (3.5–5
mg/kg) between days –12 and –7 to target a 90–95% depletion of
circulating T cells. ATG levels were undetectable by day 0, ex-
cluding possible effects on donor T cells. On day 0, dogs were
given 1 Gy TBI and marrow from dog leukocyte antigen-identical
donors. Median cell doses infused (millions/kg) were: total nucle-
ated cells (TNC)  263; CD34  6.6 and CD3  18. Posttrans-
plant immunosuppression was MMF/CSP for 4 and 5 weeks,
respectively. All recipients showed initial donor chimerism, with
maximal values ranging from 10–75% (median 25%) for granulo-
cytes and 5–40% (median 25%) for mononuclear cells. Four dogs
rejected their grafts after a median of 9.5 weeks (range 8–18
weeks), without cytopenias, and they reverted to autologous hema-
topoiesis. The 5th dog has remained a long-term mixed chimera
(36 weeks). The median times to rejection were 11 weeks (pro-
jected) in the study group and 10 weeks in the control group, not
given ATG (p  0.20, log-rank test). Analysis of the impact of cell
doses suggested that TNC had the highest Spearman correlation
coefﬁcient with the duration of donor chimerism, 0.82 (p  0.09).
We conclude that ATG reliably depleted circulating T cells by
90–95% and lymph node T cells by approximately 50%. Even so,
administering ATG before an otherwise inadequate conditioning
dose of 1 Gy TBI failed to lead to uniform stable hematopoietic
engraftment.
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Background: Anemia is a common ﬁnding in patients with
malignancies and is associated with reduced survival times. The
impact of anemia on survival during allogeneic bone marrow trans-
plantation (alloBMT) was not known. Recently, we identiﬁed that
low pre-transplant hemoglobin (PT-Hb) levels were associated
with increased mortality during the ﬁrst 6 months after BMT.
However, the impact of the PT-Hb on long-term survival was not
known. Study Design and Methods: Data from 519 consecutive
patients receiving transplants between January 1995 and March
2000 were retrospectively reviewed and survival was evaluated with
regard to risk factors, including the PT-Hb until June 2002. Sur-
vival was calculated using Kaplan-Meier limit methods. Risk factor
subgroups were compared with the log rank test. The PT-Hb
levels were determined within 2 weeks of conditioning chemora-
diotherapy. Results: PT-Hb levels correlated inversely with sur-
vival. The percentile 5-year survival of patients with PT-Hb levels
of 100, 101-110, 111-120, 121-130 and 130 g/L were 35, 29,
46, 62, and 57, respectively, not taking into account any other
known transplant-related risk factors. Patients with PT-Hb levels
of 110 g/L compared to 110 g/L had 5-year survival rates of
33% versus 56% (p  0.001). The effect of the PT-Hb on survival
was sustained in subgroups of patients presenting with low or
high-risk disease at the time of BMT. The overall 5-year survival
rate was 46%. By univariate analyses, the PT-Hb, the use of
unrelated donors, BMT in patients with more advanced disease
and major ABOmismatch between donor and recipient were found
to be signiﬁcant risk factors for mortality. In a multivariate model,
a low PT-Hb level was found to be an independent risk factor (p
0.001; hazard ratio, 1.19 per 10 g/L decrease; 95% CI, 1.10–1.28).
Conclusion: Pre-transplant anemia is an independent risk factor
for increased long-term mortality during alloBMT. It remains to
be determined whether decreased survival is the result of direct
effects from anemia or, alternatively, a low PT-Hb level may
represent surrogate marker for other adverse transplant-related
parameters.
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LOW DOSE TOTAL BODY IRRADIATION, FLUDARABINE AND ANTI-
THYMOCYTE GLOBULIN CONDITIONING FOR MULTIPLE MYELOMA
(MM)
Grosskreutz, C.L., Scigliano, E., Fruchtman, S.M., Luis, I.M. Mount
Sinai Medical Center, New York, NY.
Seven patients with multiple myeloma underwent non-myeloab-
lative stem cell transplant (NST) with ATG 15 mg/kg/day days -4
to -1, TBI 200 cGy on a single fraction on day -5, and ﬂudarabine
30 mg/m2/day on days -4 to -2. Immunosuppressive therapy was
oral mycophenolate mofetil 15 mg/kg every 12 hours and cyclo-
sporine 6 mg/kg every 12 hours started on day -5. Grafts were
unmanipulated PBPC mobilized with ﬁlgrastim 10 ug/kg/day and
collected on day 5. The median age of the recipients was 54 years
(range, 38-60). Three patients had 2 prior autologous stem cell
transplant (ASCT) and 3 had one prior ASCT. Three patients had
refractory MM, 2 had PR to prior therapies, 1 had relapsed disease
and 1 was in CR at the time of transplant. Three patients had
cytogenetics abnormalities: 2 had del 13q14 and 1 del q20. Three
patients had monoclonal IgG kappa, 2 IgA kappa and 2 kappa light
chains. Six patients received a full match related graft and one had
full match (10/10) unrelated donor graft. Five of seven patients
were evaluable for chimerism. Three had 90% and 2 had 80%
donor chimerism by day 30. Four patients are alive two of them in
CR with a follow up time of 307 and 951 days. One of them had
refractory disease at the time of NST. One patient is 61 days post
transplant in PR showing continued response. One patient is 93
days post transplant and has a mixed response evidenced by com-
plete disappearance of plasma cells in bone marrow and normal
IPEP but a new plasmacytoma in the skull. Three patients died; 2
from infectious complications on days 40 and 57 and one at day 19
with CNS toxicity presumed secondary to ﬂudarabine. One patient
developed pulmonary aspergillosis and CMV disease, both re-
solved with appropriate therapy. Three patients developed acute
GvHD, 2 had cutaneous grade I and 1 grade III of liver, gut and
skin (unrelated donor graft). All 3 are alive with resolution of the
GvHD.The addition of ATG to low dose TBI, ﬂudarabine NST
conditioning results in high rate of donor chimerism, preserved
graft versus myeloma effect and might help decrease the incidence
or severity of GvHD by in vivo T-cell depletion. These results
provide an alternative to reduced intensity conditioning with mel-
phalan for allogeneic transplantation in MM.
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IMPROVING DOSING PRECISION IN BUSULFAN (BU)-BASED PREPAR-
ATIVE REGIMENS FOR HEMATOPOIETIC STEM CELL TRANSPLANTA-
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Variation in po Bu absorption and metabolism in patients (Pts)
undergoing HSCT contributes to increased relapse rate and excess
toxicity. PK studies with ivBu conﬁrm minimal variation in area
under the concentrationXtime curve (AUC) in serial doses given to
individual Pts and reduction in variation in time to max dose, but
little decrease in interpatient variation. These studies suggest that
dosing to achieve a precise drug exposure based upon test dose PK
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